Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. WV BioHistory (TM)
Career
Job Search Post a Job Destination WV
News/Events
Industry News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Drug Development Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
About
 Advertising
 Feedback
 Home
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: National Center for Missing & Exploited Children
Jobs
 
Advertising
 

Earn a UW master’s or certificate in medical engineering or pharmaceutical bioengineering.

ORCA Annual Meeting Registration: Sept. 22 (PDF 165 kb) - Sign up now!

Institutional Review Boards

The New Drug Development Process.

Institutional Review Boards (IRB) are used to ensure the rights and welfare of people participating in clinical trials both before and during their trial participation. IRBs at hospitals and research institutions throughout the country make sure that participants are fully informed and have given their written consent before studies ever begin. IRBs are monitored by the FDA to protect and ensure the safety of participants in medical research.

An IRB must be composed of no less than five experts and lay people with varying backgrounds to ensure a complete and adequate review of activities commonly conducted by research institutions. In addition to possessing the professional competence needed to review specific activities, an IRB must be able to ascertain the acceptability of applications and proposals in terms of institutional commitments and regulations, applicable law, standards of professional conduct and practice, and community attitudes. Therefore, IRBs must be composed of people whose concerns are in relevant areas.

For more information, see the IRB Operations and Clinical Requirements list provided by FDA's Office of Health Affairs. This document is intended to help IRB's carry out their responsibilities for protection of research subjects. Also see the March 13, 1975, Federal Register, and the Technical Amendments concerning "Protection of Human Subjects" (45 CFR Part 46).

Source: U.S. Food and Drug Administration Center for Drug Evaluation and Research Handbook.


Back to The New Drug Development Process

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 2010 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

WestVirginiaLifeScience.com is owned and published by Info.Resource, Inc..